Urinalysis Market Projected to Surpass USD 8.97 Billion by 2031, Witnessing 9.70% CAGR Growth

Global Urinalysis Market size was valued at USD 3.9 billion in 2022 and is poised to grow from USD 4.28 billion in 2023 to USD 8.97 billion by 2031, growing at a CAGR of 9.70% during the forecast period (2024-2031).

Global Urinalysis Market size was valued at USD 4.28 billion in 2023 to USD 8.97 billion by 2031, growing at a CAGR of 9.70% during the forecast period (2024-2031).

The Urinalysis Market is driven by rise in the prevalence of diseases such as renal, diabetes, and urinary tract infections (UTIs). For instance, in a National Diabetes Statistics Report by 2020, diabetes presently exists in about 34.1 million individuals in the US aged 18 years and above. About one-third of these diabetics have kidney-related comorbidities related to blood pressure and blood sugar. Urinalysis is a noninvasive diagnostic technique that informs a physician about kidney dysfunction. Therefore, the rising incidence of renal diseases is expected to drive demand for related urinalysis goods, which in turn shall further fuel market growth. Moreover, the increasing aging population, government-sponsored awareness campaigns, and related technological advancements in urinalysis are expected to drive growth within the market during the forecast period. For instance, in July 2018, ARKRAY, Inc. and Beckman Coulter, Inc. collaborated to introduce the iQ Urinalysis Workcell-a fully automated urine analyzer.

 

Get a Free Sample Research Report:https://www.skyquestt.com/sample-request/urinalysis-marketUrinalysis Market

 

Segmental Analysis

Global Urinalysis Market is segmented by Product, Test Type, Application, End User, and region. 

Based on Product, the market is segmented into Consumables, and Instruments. 

Based on Test Type, the market is segmented into Pregnancy & Fertility Tests, Biochemical Tests, and Sediment Urinalysis.

Based on Application, the market is segmented into Disease Screening, and Pregnancy & Fertility Testing. 

Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, Home Care Settings, and Research Laboratories & Institutes. 

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

 

Integration of Point-of-Care Diagnostics in Modern Healthcare

This is highlighted in the rising usage of point-of-care urine testing in scenarios characterized by increasing demands for rapid, point-of-care diagnostic solutions. There is technology that can enhance the ability of healthcare workers to make rapid judgments in various situations such as now results can be received instantly. Tests like this can enable early diagnosis and intervention that would greatly improve the patient’s outcome by delivering relevant information at the time of treatment. Point-of-care urinalysis helps expedite healthcare delivery by eliminating any need for laboratory processing and minimization of waiting times. This kind of testing is predicted to be integrated into more hospitals as there is a growing emphasis on efficiency and patient-centered care.

Within the last year, some of the most notable acquisitions have involved Danaher buying Beckman Coulter, a major supplier of laboratory instruments and consumables, while Abbott acquired Alere, the largest point-of-care diagnostics provider.

 

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/urinalysis-market

 

This report covers following key players:

  • Siemens Healthineers AG  (Germany) 
  • F. Hoffmann-La Roche Ltd. (Switzerland) 
  • Cardinal Health (US) 
  • Danaher (US) 
  • Abbott (US) 
  • Sysmex Corporation (Japan) 
  • Thermo Fisher Scientific (US) 
  • QuidelOrtho Corporation (US) 
  • Becton, Dickinson and Company (US) 
  • Bio-Rad Laboratories, Inc. (US) 
  • EKF Diagnostics Holdings PLC (UK) 
  • Arkray, Inc. (Japan) 
  • ACON Laboratories, Inc. (US) 
  • 77 Elektronika Kft. (Hungary) 
  • URIT Medical Electronic Co., Ltd. (China) 
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China) 
  • Dirui Industrial Co., Ltd. (China) 
  • BIOBASE Group (China) 
  • Erba Mannheim (Germany) 
  • Alphatec Scientific E.I.R.L. (Peru) 
  • Teco Diagnostics (US) 
  • Analyticon Biotechnologies GmbH (Germany) 
  • Bioway Biological Technology Co., Ltd. (China)
  • High Technology, Inc. (US) 
  • Agappe Diagnostics Ltd (India) 
  • Toyobo Co., Ltd. (Japan) 
  • DIALAB GmbH (Austria) 
  • Quantimetrix (US) 
  • Biocare Corporation (Taiwan) 
  • Randox Laboratories Ltd. (UK) 
  • PZ Cormay S.A. (Poland) 
  • YD Diagnostics (South Korea) 
  • Contec Medical Systems Co., Ltd. (China) 
  • Biopanda Reagents Ltd. (UK)

 

Strategic Acquisitions and Technological Advances Driving Growth in Diagnostics

The key market players have adopted a strategy of growth, where growth includes the introduction of technological innovations, campaigns for introducing the products, acquisitions, and new product launches. In the UK, KDx Diagnostics, Inc. and Lister Hospital brought forward the URO17 non-invasive urine test in December 2021. This test focuses on the diagnosis of bladder cancer. It is non-invasive and allows the user to identify bladder cancer easily. With this introduction, its market position was developed. In addition, in 2022, it introduced the urine chemistry analyzer. This is a laboratory equipment that can be employed to measure many elements from the urine. They comprise glucose, protein, electrolytes among others.

Latest Technological Advances and Product Launches

Companies within the urinalysis market continually improve their offerings to enhance the detection and diagnostic capabilities of drugs and test faster. They are working hard towards developing and delivering the latest urinalysis products to keep pace with the ever-growing demand for diagnostic testing in medical facilities. These market leaders in the urinalysis market remain focused on R&D in a quest to introduce the latest products in the market and maintain their front runners’ position in this competition.

  • In September 2022, Sysmex Corporation released the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500). It tests urine sediment.
  • In June 2022, at-home pregnancy test kit PregaScreen launched by Mylab Discovery Solutions and hence a woman can check whether she is pregnant on her own. The company is going to enter the female health market through this test kit.

 

 

View report summary and Table of Contents (TOC):  https://www.skyquestt.com/report/urinalysis-market

 

 

This report covers following segments:

A. Product

Consumables

Instruments

 

B. Test Type

Pregnancy & Fertility Tests

Biochemical Tests

 

C. Application

Disease Screening

Pregnancy & Fertility Testing

 

The Urinalysis Market is growing due to the increased frequency of chronic diseases, aging populations, and increased occurrences of kidney and urinary tract infections. Urinalysis is one of the essential diagnostic procedures for most medical professionals; it often helps in early detection of the disease and its management. Advances in technology and analytical techniques have significantly enhanced the accuracy and reliability of urinalysis. Replacing the conventional manual methods are automated and point-of-care technologies which yield immediate and reliable results.

 

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/urinalysis-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Urinalysis Market Projected to Surpass USD 8.97 Billion by 2031, Witnessing 9.70% CAGR Growth